News

CEO, Anders Hultman, Commenting on FDA delay due to Covid-19

Jan 20, 2021

This weekend the US Food and Drug Administration (FDA) has informed that the impact of the COVID-19 pandemic and the reallocation of staff is leading to an even greater prolonged timeline for reviews of submissions. Anders Hultman, CEO of AroCell, commenting the FDA delay in an interview with Redeye.

Presentation at LabRoots 2024

Martin Shaw, Business Development at AroCell, held a presentation on the Thymidine Kinase 1 immunoassay, highlighting its significance as a valuable translational biomarker from drug discovery through to clinical trials. You can see the presentation below....

read more